Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTARHH1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAY 01	New CAS web site launched
NEWS 3	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 7	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 8	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 9	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10	JUN 29	STN Viewer now available
NEWS 11	JUN 29	STN Express, Version 8.2, now available
NEWS 12	JUL 02	LEMBASE coverage updated
NEWS 13	JUL 02	LMEDLINE coverage updated
NEWS 14	JUL 02	SCISEARCH enhanced with complete author names
NEWS 15	JUL 02	CHEMCATS accession numbers revised
NEWS 16	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 17	JUL 16	CAplus enhanced with French and German abstracts
NEWS 18	JUL 18	CA/CAplus patent coverage enhanced
NEWS 19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20	JUL 30	USGENE now available on STN
NEWS 21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 22	AUG 06	BEILSTEIN updated with new compounds
NEWS 23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 24	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 25	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27	AUG 27	USPATOLD now available on STN
NEWS 28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:25:09 ON 31 AUG 2007

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files.  For example, the EXPAND
command can only be used to look at the index in a file which has an
index.  Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of
commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:25:20 ON 31 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 AUG 2007  HIGHEST RN 945894-95-1
DICTIONARY FILE UPDATES:  30 AUG 2007  HIGHEST RN 945894-95-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10.566752\elected group.str
```



chain nodes :
24 25 29
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
13-22 15-29 18-21 20-25 23-24
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-13 6-15 7-8 7-12 8-9 8-16 9-10 9-18 10-11 11-12
13-14 14-15 16-17 17-18 19-20 19-23 20-21 21-22 22-23
exact/norm bonds :
6-15 8-16 9-18 14-15 15-29 16-17 17-18 18-21 19-20 19-23 20-21 20-25 21-22 22-23
23-24
exact bonds :
5-13 13-14 13-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 : 19 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:CLASS 25:CLASS 29:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:25:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      171 TO ITERATE

100.0% PROCESSED      171 ITERATIONS                                  1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         2636 TO     4204
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> d scan
```

L2 1 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Pyrrole-2,5-dione, 3-[1-(3-azidopropyl)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI)
MF C23 H18 N6 O2



ALL ANSWERS HAVE BEEN SCANNED

```
=> s l1 sss full
FULL SEARCH INITIATED 11:25:58 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4013 TO ITERATE

100.0% PROCESSED     4013 ITERATIONS                                43 ANSWERS
SEARCH TIME: 00.00.01

L3            43 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'CAPLUS' ENTERED AT 11:26:05 ON 31 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 31 Aug 2007  VOL 147 ISS 11
FILE LAST UPDATED: 30 Aug 2007  (20070830/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4            5 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:141061 CAPLUS
DOCUMENT NUMBER: 142:219146
TITLE: Preparation of indolyl pyrroledione compounds as neuroprotective and anti-proliferative agents
INVENTOR(S): Jaquith, James B.; Gillard, John W.; Laurent, Alain
PATENT ASSIGNEE(S): Aegera Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005014584	A1	20050217	WO 2004-CA1484	20040811
WO 2005014584	A9	20050623		
WO 2005014584	A8	20050909		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004220202	A1	20041104	US 2003-637599	20030811
US 7129250	B2	20061031		
CA 2534528	A1	20050217	CA 2004-2534528	20040811
GB 2420780	A	20060607	GB 2006-4137	20040811
DE 112004001502	T5	20061019	DE 2004-112004001502	20040811
US 2006199835	A1	20060907	US 2006-566752	20060201

PRIORITY APPLN. INFO.:

US 2003-637599	A	20030811
CA 2000-2308994	A	20000519
US 2001-276803	A2	20010518
WO 2001-CA718	A	20010518
US 2003-276803	A2	20031023
WO 2004-CA1484	W	20040811

OTHER SOURCE(S): CASREACT 142:219146; MARPAT 142:219146
GI

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB Indolyl pyrroledione compds., e.g. of formula I [X1-X3, X5-X8 = C, N; X4, X9, = CH, N; R1-R3, R6-R8 = absent, O, H, alkyl, halo, N3, CN, nitro, etc.; R4 = H, (substituted) alkyl, etc.; R5 = absent, H, (substituted) alkyl, etc.], are prepared which are useful in the treatment of proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. Thus, II was prepared, and had IC50 of 3 μM against H460 cells after 24 h.

IT 844467-88-5P 844467-90-9P 844467-92-1P
844467-93-2P 844467-95-4P 844467-97-6P
844467-99-8P 844468-02-6P 844468-03-7P
844468-04-8P 844468-05-9P 844468-06-0P
844468-07-1P 844468-09-3P 844468-10-6P
844468-11-7P 844468-12-8P 844468-13-9P
844468-15-1P 844468-16-2P 844468-17-3P
844468-18-4P 844468-20-8P 844468-22-0P
844468-23-1P 844468-24-2P 844468-25-3P
844468-26-4P 844468-27-5P 844468-28-6P
844468-30-0P 844468-33-3P 844468-36-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indolyl pyrroledione compds. as antitumor and anti-inflammatory agents)

RN 844467-88-5 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844467-90-9 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(3-methyl-1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844467-92-1 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-2,5-dioxo-4-[5-(phenylmethoxy)-1H-indol-1-yl]-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844467-93-2 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-(phenylmethoxy)-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844467-95-4 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(3-methyl-1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-(phenylmethoxy)-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844467-97-6 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(2-methyl-1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-(phenylmethoxy)-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844467-99-8 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(2-methyl-1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844468-02-6 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-methoxy-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844468-03-7 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-fluoro-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844468-04-8 CAPLUS
CN Carbamimidothioic acid, 3-[3-[4-(5-fluoro-1H-indol-1-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844468-05-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-[(4,5-dihydro-1H-imidazol-2-yl)thio]propyl]-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-06-0 CAPLUS
CN Carbamimidothioic acid, 3-[3-[4-(2,3-dihydro-1H-indol-1-yl)-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844468-07-1 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1H-indol-1-yl)-2,5-dioxo-1H-pyrrol-3-yl]-5-[(phenylthio)methoxy]-1H-indol-1-yl]propyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844468-09-3 CAPLUS
CN Carbamimidothioic acid, 3-[1-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-3-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844468-10-6 CAPLUS
CN Carbamimidothioic acid, 3-[1-[2,5-dihydro-4-[1-methyl-5-(phenylmethoxy)-1H-indol-3-yl]-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-3-yl]propyl ester (9CI) (CA INDEX NAME)



RN 844468-11-7 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[3-(dimethylamino)propyl]-1H-indol-1-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 844468-12-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[3-[(4,5-dihydro-1H-imidazol-2-yl)thio]propyl]-1H-indol-1-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 844468-13-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-(3-aminopropyl)-1H-indol-1-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 844468-15-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-16-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 844468-17-3 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-[5-(phenylmethoxy)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 844468-18-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-20-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-22-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844468-23-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(5-fluoro-1H-indol-1-yl)-4-[1-(3-hydroxypropyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 844468-24-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-25-3 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-5-(phenylmethoxy)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 844468-26-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-27-5 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-[5-(phenylmethoxy)-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 844468-28-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(2-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-30-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-5-(phenylmethoxy)-1H-indol-3-yl]-4-(3-methyl-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 844468-33-3 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-36-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-(3-hydroxypropyl)-1H-indol-1-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



IT 844468-14-0P 844468-32-2P 844468-38-8P
844468-39-9P 844468-40-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolyl pyrroledione compds. as antitumor and anti-inflammatory agents)

RN 844468-14-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-hydroxypropyl)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 844468-32-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-azidopropyl)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 844468-38-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-(3-azidopropyl)-1H-indol-1-yl]-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 844468-39-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[3-[(methylsulfonyl)oxy]propyl]-1H-indol-1-yl]- (9CI) (CA INDEX NAME)



RN 844468-40-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-1-yl)-4-[1-[3-[(methylsulfonyl)oxy]propyl]-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:851162 CAPLUS
DOCUMENT NUMBER: 136:6198
TITLE: Neuroprotective and anti-proliferative analogs of staurosporine and granulatimide, namely 3-(1H-indol-3-yl)-1H-pyrrole-2,5-diones, 3-(1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-diones, and pyrrolo-β-carboline derivatives, and their preparation and use as modulators of apoptosis
INVENTOR(S): Jaquith, James B.; Fallis, Alex; Gillard, John
PATENT ASSIGNEE(S): Aegera Therapeutics Inc., Can.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087887	A2	20011122	WO 2001-CA718	20010518
WO 2001087887	A3	20020228		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2308994	A1	20011119	CA 2000-2308994	20000519
CA 2409355	A1	20011122	CA 2001-2409355	20010518
EP 1283836	A2	20030219	EP 2001-935858	20010518
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004509068	T	20040325	JP 2001-584281	20010518
US 2004220202	A1	20041104	US 2003-637599	20030811
US 7129250	B2	20061031		
US 2004102467	A1	20040527	US 2003-276803	20031023

PRIORITY APPLN. INFO.:			
	CA 2000-2308994	A	20000519
	US 2001-276803	A2	20010518
	WO 2001-CA718	W	20010518
	US 2003-276803	A2	20031023

OTHER SOURCE(S): MARPAT 136:6198
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention features 3-(1H-indol-3-yl)-4-(1H-indol-1-yl)-1H-pyrrole-2,5-diones of formula I, ring-substituted pyrrolo-β-carboline derivs. of formula II, and 3-(1H-indol-3-yl)-1H-pyrrole-2,5-diones of formula III, which are useful as neuroprotective and anti-proliferative compds. [wherein: A1, B1 = H, alkyl; A2, B2 = H, OH or ethers, SH or thioethers; or A1A2 or B1B2 = oxo; or B1B2 = thioxo in III; X1-3 = C, N; X4 = CH or N; only 0-2 of X1-4 = N; X5 = N, C, S, or CH; X6-8 = C, N; X9 = CH or N; only 0-2 of X6-9 = N; R1-3, R6-8 = lone pair or oxido when bound at X = N, otherwise = H, (un)substituted alkyl, halo, N3, cyano, NO2, NH2 or derivs., OH or derivs., SH or derivs., C.tplbond.CH or derivs.; R4, R5 = H, wide variety of linear and substituted sidechains, possibly including amino acid or sugar residues; or R4R5 form a ring; Y = H, halo, OH, or alkyl]. Also disclosed are methods for the preparation of these compds., selected biol. profiles and uses of these compds. in the treatment of various neurodegenerative and inflammatory diseases of the human nervous

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

system, and in the treatment of various other proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. Over 100 compds. were prepd. and individually claimed. A variety of bioassays were performed on selected compds. For instance, 5-methoxyindole was treated with oxalyl chloride and then aq. ammonium carbonate to give 5-methoxy-α-oxoindole-3-acetamide (IV). In a sep. reaction, indole was N-alkylated with BrCH2CO2Et using KOBu-tert in THF, and the product was cyclized with IV in situ, to give title compd. V. Cyclization of V using Me3SiOSO2CF3 in CH2Cl2 with concomitant oxidn. over 3 days gave title compd. VI. Both V and VI inhibited killing of mouse cerebral granule neurons by cisplatin in vitro, with an identical IC50 value of 10 μM. Biol. results suggest that the compds. prevent cell death by interfering with the apoptotic cascade at a point upstream of the caspases, i.e., the inhibition of one or several of the serine/threonine protein kinases directly upstream of the caspases. The compds. did not, however, significantly protect cancer cells from apoptosis. Furthermore, selected compds. down-regulated endogenous levels of HIAP1 mRNA in the neuroblastomal cell line LAN5, and thus represented new chemotherapeutics for treatment of cancer.

IT 374817-56-8P, 3-[1-(2-Hydroxyethyl)-5-benzyloxyindol-3-yl]-4-(indol-1-yl)-1H-pyrrole-2,5-dione 374817-57-9P, 3-[1-(2-Hydroxyethyl)-5-benzyloxyindol-3-yl]-4-(5-methoxyindol-1-yl)-1H-pyrrole-2,5-dione 374817-58-0P, 3-[1-(2-Hydroxyethyl)-5-benzyloxyindol-3-yl]-4-(6-methoxyindol-1-yl)-1H-pyrrole-2,5-dione 374817-60-4P, 3-[1-(2-Hydroxyethyl)indol-3-yl]-4-(indol-1-yl)-1H-pyrrole-2,5-dione
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of indolylpyrroledione and pyrrolo-β-carbolines as neuroprotective and antiproliferative agents)

RN 374817-56-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(2-hydroxyethyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 374817-57-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(2-hydroxyethyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(5-methoxy-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 374817-58-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(2-hydroxyethyl)-5-(phenylmethoxy)-1H-indol-3-yl]-4-(6-methoxy-1H-indol-1-yl)- (9CI) (CA INDEX NAME)



RN 374817-60-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(2-hydroxyethyl)-1H-indol-3-yl]-4-(1H-indol-1-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:41230 CAPLUS
DOCUMENT NUMBER: 116:41230
TITLE: Inhibitors of protein kinase C. 1. 2,3-bisarylmaleimides
AUTHOR(S): Davis, Peter D.; Hill, Christopher H.; Lawton, Geoffrey; Nixon, John S.; Wilkinson, Sandra E.; Hurst, Steven A.; Keech, Elizabeth; Turner, Susan E.
CORPORATE SOURCE: Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(1), 177-84
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 116:41230
GI



I

AB A series of novel inhibitors, i.e., maleimides I (R = H, Me; R1 = (un)substituted indolyl, (un)substituted Ph, naphthyl, benzo[b]thien-3-yl, benzo[b]furan-3-yl, 3-pyrrolyl) of protein kinase C (PKC) is described. These maleimides were derived from the structural lead provided by the indolocarbazoles, staurosporine and K252a. Optimum activity required the imide NH, both carbonyl groups, and the olefinic bond of the maleimide ring. Bisindolylmaleimides were the most active and the potency of these was improved by a chloro substituent at the 5-position of one indole ring (IC50 0.11 μM). In a series of (phenylindolyl)maleimides, nitro derivative I (R = Me, R1 = 2-O2NC6H5) was most active (IC50 0.67 μM). Naphthalene compound I (R = Me, R1 = 1-naphthyl) and benzothiphene compound I (R = Me, R2 = benzo[b]thien-3-yl) showed greater than 100-fold selectivity for inhibition of PKC over the closely related cAMP-dependent protein kinase.
IT 125314-23-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and protein kinase C inhibiting activity of)
RN 125314-23-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:42473 CAPLUS
DOCUMENT NUMBER: 114:42473
TITLE: A mild conversion of maleic anhydrides into maleimides
AUTHOR(S): Davis, Peter D.; Bit, Rino A.
CORPORATE SOURCE: Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY, UK
SOURCE: Tetrahedron Letters (1990), 31(36), 5201-4
CODEN: TELEAY; ISSN: 0040-4039
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 114:42473
GI



I

AB Maleic anhydrides I [X = O; R = R1 = Me, Ph, N-methyl-3-indolyl; R = N-methyl-3-indolyl, R1 = N-(3-cyanophenyl)-3-indolyl, N-methyl-5-methoxycarbonyl-3-indolyl, 2-indolyl] are converted into maleimides I (X = NH) at room temperature and in excellent yield by treatment with a mixture of methanol and hexamethyldisilazane. Esters and nitriles are unaffected under these conditions.
IT 125314-23-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, by imidation of maleic anhydride with hexamethyldisilazane and methanol)
RN 125314-23-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:98378 CAPLUS
DOCUMENT NUMBER: 112:98378
TITLE: Preparation of 3-(3-indolyl)pyrrole-2,5-diones and analogs as protein kinase inhibitors
INVENTOR(S): Davis, Peter David; Hill, Christopher Huw; Lawton, *Geoffrey
PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
SOURCE: Eur. Pat. Appl., 38 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 328026	A1	19890816	EP 1989-102025	19890206
EP 328026	B1	19930428		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8900865	A	19891025	ZA 1989-865	19890203
CZ 280738	B6	19960417	CZ 1989-752	19890203
SK 278989	B6	19980506	SK 1989-752	19890203
AU 8929658	A	19890810	AU 1989-29658	19890206
AU 623630	B2	19920521		
HU 49348	A2	19890928	HU 1989-554	19890206
HU 201054	B	19900928		
US 5057614	A	19911015	US 1989-307104	19890206
AT 88704	T	19930515	AT 1989-102025	19890206
CA 1320194	C	19930713	CA 1989-590178	19890206
ES 2054890	T3	19940816	ES 1989-102025	19890206
DK 8900558	A	19890811	DK 1989-558	19890207
DK 171891	B1	19970804		
JP 01233281	A	19890919	JP 1989-27741	19890208
JP 07030071	B	19950405		
NO 8900568	A	19890811	NO 1989-568	19890209
NO 172540	B	19930426		
NO 172540	C	19930804		
SU 1799382	A3	19930228	SU 1989-4613492	19890209
FI 8900652	A	19890811	FI 1989-652	19890210
FI 96861	B	19960531		
FI 96861	C	19960910		
US 36736	E	20000613	US 1998-14198	19980127
PRIORITY APPLN. INFO.:			GB 1988-3040 A	19880210
			GB 1988-27565 A	19881125
			EP 1989-102025 A	19890206
			US 1989-307104 A5	19890206

GI



I II

AB The title compds. (I; R1, R2 = H, alkyl, aryl, etc.; R3 = aryl, heteroaryl; R4-R7 = H, halo, alkyl, alkoxy, etc.; 1 of X, Y = O and the other = O, S, H and OH, H and H) were prepared Thus, 1-(3-bromopropyl)indole (preparation given) was stirred 2 h with (COCl)2 in CH2Cl2 and the product stirred 3 h with 1-methyl-3-indolylacetic acid in CH2Cl2

L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
contg. (Me2CH)2NEt to give bis(indolyl)furandione II (R = Br, Z = O) which was converted in 3 steps to II (R = NH2, Z = NH). The latter was stirred 16 h with 1,1'-thiocarbonyldiimidazole in THF to give II (R = NCS, Z = NH) which had IC50 of 0.008 μM for inhibition of protein kinase C in vitro.
IT 125314-23-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as protein kinase inhibitor)
RN 125314-23-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-1-yl)-4-(1-methyl-1H-indol-3-yl)- (9CI) (CA INDEX NAME)



```
=> log hold
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                30.11     202.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -3.90      -3.90

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:31:02 ON 31 AUG 2007
```

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	2	"7129250".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:28
S2	2	"5057614".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:31
S3	6	"??276803".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:32
S4	0	"??276803".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:32
S5	0	"?276803".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:32
S6	6	"??276803".did.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:33
S7	0	"2308994".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36

EAST Search History

S8	0	"0102467".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S9	2	"0102467".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S10	0	"$-0102467".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S11	2	"$0102467".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S12	2	"????0102467".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S13	0	"10276803".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36
S14	0	"10/276803".an.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/02/21 10:36

EAST Search History

S15	6	"566752".ap.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/08/31 11:52
S16	4	"36736".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/08/31 11:57
S17	0	"36736"".pn.328026"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/08/31 11:57
S18	48	"328026"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/08/31 11:57